Norovirus is a very contagious virus (infection) sometimes referred to as a “stomach bug”. Norovirus commonly causes vomiting, diarrhea, sudden nausea (the feeling of wanting to vomit), and stomach cramps. It may also cause fever, headache and body aches.
Transmission (spread) of norovirus can occur by having direct contact with an infected person, consuming food or water contaminated with the virus and/or by touching contaminated surfaces and then putting unwashed hands in your mouth.
It is an illness which you can acquire (catch) many times in your life because there are so many different types of noroviruses. People of all ages throughout the world can become infected and sick with norovirus; however, the elderly are more likely to catch the virus.
Vaccines are a type of medicine designed to prevent people acquiring (developing) illness from infections before they have come into contact with the infection. Vaccines do not treat an infection once it has been caught. To prevent infections, vaccines act in the body to cause your immune system (the body’s defence system) to produce antibodies (proteins in your blood). Antibodies recognize and destroy disease-causing organisms (such as viruses) and stop them from infecting human cells.
The Bivalent GI.1/GII.4 vaccine is a new vaccine being developed by Vaxart, Inc. to prevent healthy adults from acquiring (catching) Norovirus. VXA-G1.1-NN and VXA-G2.4-NS are separate oral (taken by mouth) tablets taken one after the other to make up this Norovirus vaccine.
The purpose of this study is to assess the immune response of the Bivalent GI.1/GII.4 vaccine against Norovirus in healthy adults, as well as how safe the vaccine is.
New (investigational) medications, drugs and devices must be approved for use by the United States Food and Drug Administration (FDA).
The Bivalent GI.1/GII.4 vaccine is an experimental vaccine. This means that it is not an approved vaccine to prevent healthy adults from acquiring Norovirus in the United States or in any other country.
This research is being sponsored and conducted by Vaxart Inc.
Transmission (spread) of norovirus can occur by having direct contact with an infected person, consuming food or water contaminated with the virus and/or by touching contaminated surfaces and then putting unwashed hands in your mouth.
It is an illness which you can acquire (catch) many times in your life because there are so many different types of noroviruses. People of all ages throughout the world can become infected and sick with norovirus; however, the elderly are more likely to catch the virus.
Vaccines are a type of medicine designed to prevent people acquiring (developing) illness from infections before they have come into contact with the infection. Vaccines do not treat an infection once it has been caught. To prevent infections, vaccines act in the body to cause your immune system (the body’s defence system) to produce antibodies (proteins in your blood). Antibodies recognize and destroy disease-causing organisms (such as viruses) and stop them from infecting human cells.
The Bivalent GI.1/GII.4 vaccine is a new vaccine being developed by Vaxart, Inc. to prevent healthy adults from acquiring (catching) Norovirus. VXA-G1.1-NN and VXA-G2.4-NS are separate oral (taken by mouth) tablets taken one after the other to make up this Norovirus vaccine.
The purpose of this study is to assess the immune response of the Bivalent GI.1/GII.4 vaccine against Norovirus in healthy adults, as well as how safe the vaccine is.
New (investigational) medications, drugs and devices must be approved for use by the United States Food and Drug Administration (FDA).
The Bivalent GI.1/GII.4 vaccine is an experimental vaccine. This means that it is not an approved vaccine to prevent healthy adults from acquiring Norovirus in the United States or in any other country.
This research is being sponsored and conducted by Vaxart Inc.
Show More
